Global pharma giants Eli Lilly and Novo Nordisk are scrambling to cement their lead in India's booming obesity drug market before cheaper generic versions hit shelves in March next year.
The Print on MSN
To do homeowners ‘complete justice’, SC sets up panel to finish stalled Noida Supertech project
Ending years of uncertainty for Supernova buyers, top court steps in to oversee construction, prevent pressure from lender on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback